GLOW Peptide Dosage Calculator and Protocol Guide

GLOW Peptide Dosage

A standard 70 mg GLOW vial contains three peptides in fixed mass ratios: 50 mg GHK-Cu, 10 mg BPC-157, and 10 mg full-length TB-4.

The standard 2.8 mg GLOW dose contains 2 mg GHK-Cu and 400 mcg each of BPC-157 and TB-4. The 12-week schedule keeps that dose constant while frequency falls: daily in weeks 1–4, 5x per week in weeks 5–8, and 2-3x per week in weeks 9–12.

Skin repair slows with age across several connected systems: collagen genes fire less, capillary supply thins, and repair cells lose coordination. By design, GLOW assigns one peptide to address each bottleneck.

The GLOW peptide blend contains three peptides in a fixed 50/10/10 mg ratio:

• GHK-Cu — Builds new collagen and clears damaged tissue at the same time.¹ Most collagen interventions only do the first; this is what makes GLOW a skincare stack.
• BPC-157 — Sprouts new small blood vessels into the dermal repair area (angiogenic signaling²). Without that capillary supply, GHK-Cu has the signal but no nutrient delivery to the treatment site.
• TB-4 (full-length thymosin β4, 43 aa) — Moves repair cells into position and biases healing toward functional tissue rather than rope-like scarring.³ ⁴

GLOW uses the full-length TB-4 parent, not the shorter TB-500 fragment; the two are blurred on labels routinely.⁵ Confirm what sequence is in the vial by reviewing third-party lab reports.

GLOW coordinates three jobs that skin remodeling needs at the same time. GHK-Cu changes the repair instructions, BPC-157 supports the capillary supply, and TB-4 gives repair cells the internal structure they need to move through tissue. The blend has not been tested as a complete formulation; its rationale comes from the complementary mechanisms of the three peptides.

GHK-Cu: collagen and structure

What it is

GHK-Cu is a three-amino-acid peptide bound to copper. It carries copper into the repair processes that build and organize the skin’s structural matrix.

How it works

GHK-Cu changes which repair instructions skin cells follow, increasing collagen, elastin, and antioxidant production while helping clear damaged tissue. Its copper also supports lysyl oxidase, the enzyme that cross-links new collagen fibers and gives the matrix strength (gene regulation, tissue clearing, and collagen cross-linking¹).

Role in GLOW

GHK-Cu addresses both sides of skin remodeling: removing damaged matrix and building its replacement. It is the main rebuilding signal in GLOW, while BPC-157 supports the blood supply and TB-4 helps position repair cells.

Evidence

GHK-Cu is associated with regulation across more than 4,000 genes, including collagen synthesis, antioxidant defense, wound healing, inflammation, and tissue breakdown. Circulating levels decline with age, from roughly 200 ng/mL at age 20 to about 80 ng/mL by 60.¹

Small split-face human dermatology studies, usually with fewer than 50 participants per arm, report changes in wrinkle depth and skin density. The strongest human evidence is topical; it does not establish how much injected GLOW changes human skin. No multi-center RCT has evaluated GLOW or injectable GHK-Cu for this use.¹

BPC-157: blood supply

What it is

BPC-157 is a synthetic 15-amino-acid peptide modeled from a protective protein fragment found in gastric juice. Its role in GLOW is to support the blood supply behind tissue repair rather than build collagen directly.

How it works

BPC-157 signals blood-vessel cells to relax existing vessels, move into damaged tissue, and form new capillaries. In tendon repair cells, it also increased the number of places where growth hormone can attach; it made the cells more responsive when growth hormone was present without activating the signal on its own (new blood vessel formation²).

Role in GLOW

Active skin remodeling needs oxygen, nutrients, and a route for repair cells to reach the area. BPC-157 supports that supply layer so oxygen and nutrients can reach the tissue while GHK-Cu and TB-4 do their repair work.

Evidence

More than 100 preclinical repair studies support BPC-157's blood-vessel signaling and repair-cell effects. The limited human evidence includes:

• A randomised double-blind placebo-controlled Phase 2 enema trial in ulcerative colitis with 53 participants, published only as a meeting abstract. Its confidence interval spans zero and is wider than the point estimate, so it was too small to detect the difference it observed — uninformative rather than null.
• An intra-articular knee series with 16 patients analysed. Fourteen improved, and 7 of 12 reported durable improvement beyond six months by telephone follow-up.
• A hamstring registration with estimated enrollment and no disclosed dose. It remains provenance-flagged and registered-unverified.

No human study shows that SubQ BPC-157 builds new capillaries in skin or improves a GLOW outcome. No published receptor binding constant or characterised minimum effective concentration anchors the dose, so dose decisions rest on preclinical envelopes.²

TB-4: cell migration

What it is

TB-4 is a naturally occurring 43-amino-acid peptide involved in cell movement and tissue repair. It is not the same molecule as TB-500, the shorter 17–23 fragment, even when product labels use the names interchangeably.⁵

How it works

Repair cells move by building and releasing an internal scaffold made from actin. TB-4 holds loose actin in reserve so the scaffold can be assembled where it is needed. TB-4 can also release Ac-SDKP, a smaller peptide studied for anti-scarring and anti-inflammatory effects (actin sequestration and Ac-SDKP release³ ⁴).

Role in GLOW

TB-4 supports the movement of repair cells through damaged tissue and the organization of the rebuilding process. Its role complements GHK-Cu: TB-4 helps position the repair cells, while GHK-Cu handles more of the matrix-building work.

Evidence

Full-length TB-4 has human clinical research across corneal, cardiac, and wound-repair programs, including clean Phase 1 safety data, plus dermal wound-healing models. Those studies support the broader repair mechanism. They do not establish the efficacy of a 400 mcg SubQ dose in GLOW, and their findings cannot be assigned to a TB-500 fragment vial.³ ⁴ ⁵ ⁶

Regulatory Status

GLOW as a pre-mixed blend has not been evaluated by the FDA. The current compounding review applies to its individual compounds rather than GLOW as a finished formulation.

GHK-Cu

• Injectable GHK-Cu was moved to Category 2 in September 2023.
• GHK-Cu will return to PCAC for a vote before the end of February 2027.
• HHS has announced that GHK-Cu is expected to return to Category 1, which would restore compounding access for injectable formulations.⁸

BPC-157

• On 23 July 2026, PCAC voted to recommend adding BPC-157 to the 503A Bulks List, against FDA staff, who had recommended against listing.
• BPC-157 was removed from Category 2 on 22 April 2026 by nominator withdrawal rather than because a safety concern was resolved.
• The BPC-157 evaluation covered ulcerative colitis only, and the vote counts are contested across the source documents, so no tally is quoted here as primary-sourced.
• Final FDA action on BPC-157 is still pending.

TB-4

• The July 23, 2026 PCAC recommendation covered TB-500, not the full-length TB-4 used in GLOW.
• TB-500 is a fragment of the full-length thymosin beta-4 (43 amino acids), and the full-length TB-4 has substantially more human safety data than the fragment.
• Vendors often use the TB-4 and TB-500 names interchangeably, or confuse the two.

The operative status for BPC-157 and TB-500 is recommended for listing, pending FDA action. A committee recommendation is not a rule; notice-and-comment rulemaking follows and can take over a year.

These are access-pathway questions rather than therapeutic approval. The dosing below draws from the per-component research and is reflected in the FDA review committee documents for each peptide, which aligns with PeptideFox’s previous research.

GLOW Dosing Protocol

The standard protocol for GLOW is 2.8 mg per injection: 2 mg GHK-Cu with 400 mcg each of BPC-157 and TB-4.

• Reconstitute a GLOW-70 vial by adding 2.5 mL of BAC water
• That delivers a concentration of 28 mg/mL
• The resulting dose per injection: 2.8 mg ÷ 28 mg/mL = 0.1 mL or 10-units on a U-100 insulin syringe

Each 70 mg vial of GLOW supplies 25 daily doses and remains within the 28-day refrigerated-use window. The time of day is inconsequential — consistency is far more important.

Note: GLOW has no trial-established dose that combines the three compounds; the dose is derived by combining the ranges of each individual peptide.

12-week GLOW protocol for skincare

The GLOW protocol runs for 12 weeks, split up into three phases, followed by 4–8 weeks off. The 2.8 mg dose remains fixed while frequency decreases from daily -> 5x per week -> 2-3x per week.

No controlled trial has tested this schedule or established when skin changes should appear — and while reports on public forums are extensive, each individual may respond differently. In addition, the Supporting Factors — such as sleep and hydration — will materially affect results.

Phase 1: Activation (Weeks 1–4)

Dose: Daily

• GHK-Cu activates collagen production while its copper component enables proper structural cross-linking¹
• BPC-157 builds the network of small blood vessels needed to feed active tissue²
• TB-4 mobilizes and organizes repair cells³

Expected: Skin hydration improves, tone evens, and texture softens.

Baseline photos. Progress on skin is gradual; week-0 photos are the only reliable progress marker at week 6.

Phase 2: Remodeling (Weeks 5–8)

Dose: 5x per week

Same per-injection amounts. All compounds at peak coordinated activity.

• GHK-Cu drives maximum collagen production — structural proteins, elastin for bounce-back, and the water-binding molecules that keep skin hydrated from within¹
• BPC-157 maintains blood flow to active tissue²
• TB-4 coordinates efficient cell organization³

Expected: Fine lines soften, elasticity improves, visible glow returns, and skin thickness increases.

Progress photos. Measure week 6 against the week-0 baseline.

Phase 3: Maintenance (Weeks 9–12)

Dose: 2-3x per week

Pulsed administration keeps the repair signal present without turning the protocol into constant stimulation.

• Signal sensitivity — pulsed dosing is the conservative way to avoid blunting the response over time.
• Integration time — newly synthesized collagen needs 48–72 hours between pulses to organize and cross-link.
• Maintenance fit — long-running protocols usually work better as a cadence than as daily pressure forever.

Take a 4–8-week break between GLOW cycles; none of the compounds have been studied for continuous use.

Progress photos. Compare week 12 with the week-0 baseline and week 6.

The full schedule uses 56–60 injections, and each 70 mg GLOW vial contains 25 standard doses by mass. CDC summarizes USP guidance: date an opened multi-dose vial at first puncture and discard it within 28 days unless the manufacturer states another opened-vial date.⁷ The dose count and 28-day window together require three vials for the 12-week protocol.

Cycled topical actives such as retinoids, vitamin C, and niacinamide are sometimes paired with GLOW during the active weeks. GLOW targets dermal structure; the topicals target surface turnover and pigmentation.

Phasing and lifestyle inputs are covered in Supporting Factors below.

GLOW is skincare-only — for injury, use the injury protocols

GLOW has no injury protocol. The fixed 50/10/10 skincare ratio does not deliver what soft tissue needs: TB-4 lands far below its cell-migration threshold, and there is no KPV to gate inflammation.

BPC-157 is the one component that does land in range, at 400 mcg against a derived position of 250-500 mcg daily — but GLOW’s frequency falls to 5x and then 2-3x weekly, where injured tissue is dosed once daily. Pushing the dose to fix any of that overdoses GHK-Cu.

Soft-tissue injury protocols dose the compounds individually instead. The BPC-157 + TB-500 Wolverine Stack covers simple repair; the Injury Recovery Protocol is the five-compound version with the TB-500 bolus (1–2.5 mg, 2-3x per week) and NAD+ that the cocktail can’t carry. For reactive or inflamed skin rather than injury, KLOW adds KPV.

Conditional Add-Ons

NAD+ is the primary metabolic add-on considered for GLOW. It may be relevant when remodeling occurs under metabolic strain — GLP-1 use, caloric deficit, or chronic fatigue. Age alone is a weaker reason than it is usually presented as: whole-blood NAD+ does not reliably fall with age, and the decline that does show up is tissue-specific and load-dependent. Strain is the signal here, not birthday.

The dose is 100–200 mg IM, 2-3x per week. NAD+ requires a different syringe and site because its acidity can degrade peptides on contact.

GLOW alone handles standard skin quality. The remaining layers are conditional — added only when a specific bottleneck shows up, not by default:

Topical GHK-Cu / AHK-Cu + minoxidil. Fits hair shedding during GLP-1 use or aggressive dieting. Either copper peptide alone works if availability or tolerance is a constraint. The underlying deficit matters too — hair follicles need direct scalp exposure plus enough protein and calories to grow.

MT-I (afamelanotide), not MT-II. Fits when pigment with photoprotection sits alongside skin-quality goals. MT-II’s central nervous-system side effects make it the wrong default.

Sermorelin / Tesamorelin / Ipamorelin. Only for the growth-hormone-deficiency pattern (poor sleep + low recovery). Not a default layer.

KLOW is the better fit when inflammation emerges or baseline reactivity is the limit. Continuous standalone KPV alongside GLOW produces the same four-peptide composition with more handling.

Tell FoxAI your situation and it builds the right stack→

Phenotype Considerations

Perimenopausal users. Estrogen-driven collagen decline accelerates during perimenopause, and substrate is typically already more depleted at baseline. The full 12-week, three-phase cycle remains the baseline rather than compressing the protocol into eight weeks; activation remains weeks 1–4.

Recent surgery. The convention defers at least two weeks after major surgery. Excessive angiogenesis during early surgical healing can complicate scar formation.

GLP-1 users / aggressive cutting. Rapid weight loss outpaces the skin’s ability to remodel, and substrate availability tightens. NAD+ from the start fits here, with the topical hair overlay where shedding emerges.

Supporting Factors

These inputs support tissue synthesis, collagen cross-linking, matrix hydration, copper balance, and overnight repair:

Optional adjuncts: red-light therapy (630–670 nm) for 10–20 minutes daily, and microneedling every three to four weeks during Phase 2.

Safety & Considerations

Active cancer or cancer history. GLOW is excluded during active cancer treatment. The blood-vessel signaling associated with GHK-Cu, BPC-157, and TB-4 creates a theoretical concern, not a measured human tumor risk.

Five years after treatment or remission is used as a conservative review window rather than a proven biological cutoff. Any use within that window requires explicit clearance and ongoing supervision from the clinician managing the cancer history; after five years, medical review still applies when recurrence risk or active surveillance remains relevant.

Wilson’s disease or copper overload. GHK-Cu delivers 50 mg copper-bound peptide per vial; contraindicated in anyone with copper-handling disorders.

Pregnancy or breastfeeding. No safety data for any of the three peptides during pregnancy.

WADA-tested athletes. TB-4 is on the prohibited list; GLOW is not usable in-competition.

Reactive or rosacea-prone skin. GLOW does not address inflammatory tone; KLOW is the better tool for these cases.

Conventional alternatives include topical retinoids and in-office collagen-induction procedures. They act through different tissue layers and carry different downtime and cost profiles.

FAQ

Related Topics

• KLOW Dosing Calculator — The 4-peptide variant with KPV for reactive or post-procedure skin
• Injury Recovery Peptide Protocol — Five-compound structural repair framework including NAD+ metabolic support
• BPC-157 + TB-500 Wolverine Stack — Simpler injury recovery stack centered on the two core repair peptides
• BPC-157 Guide — Standalone dosing, pharmacokinetics, oral vs injectable
• TB-500 / TB-4 Guide — Fragment vs full-length, CoA verification, threshold-saturation mechanism
• GHK-Cu Guide — Copper peptide mechanism for skin and matrix quality
• NAD+ Guide — Cellular energy support for intensive repair cycles
• Peptide Reconstitution Guide — General bacteriostatic water and syringe handling
• Where to Inject GLOW Peptide — Near-injury vs systemic injection routing

References

¹ GHK-Cu tissue-organization signaling and copper-peptide complex — TGF-β/Smad matrix organization, lysyl oxidase cross-linking, SOD/catalase antioxidant expression, copper coordination chemistry, 4,000+ gene modulation: PubMed 29986520; age-related plasma decline (roughly 200 ng/mL at age 20 to about 80 ng/mL by 60): Pickart L, Margolina A. Int J Mol Sci 2018. DOI: 10.3390/ijms19071987

² BPC-157 angiogenic signaling — VEGFR2-Akt-eNOS activation, nitric oxide bioavailability, FAK-paxillin cell-anchoring cascade, anti-cytokine modulation: PMC8275860

³ TB-4 / TB-500 G-actin sequestration and threshold-saturation mechanism — actin-monomer binding, cytoskeletal mobilization for cell migration, mass-action pharmacodynamics requiring bolus dosing: PubMed 12581423

⁴ TB-4 Ac-SDKP anti-fibrotic fragment — N-terminal tetrapeptide (fragment 1–4) released by meprin-α and POP processing; suppresses TGF-β-driven fibrosis and cardiac/renal remodeling: PMC4889319; fragment-specific activity review: PMC8724243

⁵ TB-4 / TB-500 product mislabeling — documented bidirectional mislabeling between full-length TB-4 (43 aa) and the TB-500 fragment (residues 17–23) in marketed peptide products: Esposito M et al. Drug Test Anal 2012. PubMed 22962027

⁶ TB-4 Phase 1 human safety — first-in-human randomized, double-blind, single- and multiple-dose Phase 1 of recombinant human thymosin β4 in healthy volunteers, no serious adverse events: PubMed 34346165; intravenous TB-4 Phase 1 safety and pharmacokinetics, no dose-limiting or serious adverse events (Ann N Y Acad Sci 2010;1194:223–229): NCT00743769

⁷ Centers for Disease Control and Prevention. Preventing Unsafe Injection Practices: multi-dose vial handling and beyond-use guidance. CDC injection-safety guidance

⁸ On February 27, 2026, HHS Secretary Kennedy announced that GHK-Cu is among approximately 14 peptides expected to return to Category 1.